<?xml version="1.0" encoding="UTF-8"?>
<results title="testTrace">
 <result pre="coronary syndrome and venous thromboembolism. Several medications used for the" exact="treatment" post="of COVID-19 have uncertain safety and efficacy profiles. Subject"/>
 <result pre="some patients1. However, in addition to respiratory symptoms, uncontrolled SARS-CoV-2" exact="infection" post="can trigger a cytokine storm, whereby pro-inflammatory cytokines and"/>
 <result pre="COVID-19 are strongly associated with cardiovascular disease (CVD)12â€&quot;16. A high" exact="prevalence" post="of pre-existing CVD has been observed among patients with"/>
 <result pre="which introduces a novel furin cleavage site. c | SARS-CoV-2" exact="infection" post="is triggered by the binding of the S protein"/>
 <result pre="be the predominant entry pathway used by coronaviruses in the" exact="infection" post="of cells cultured in vitro40, but the importance of"/>
 <result pre="cultured in vitro40, but the importance of this pathway for" exact="infection" post="in vivo remains unclear. After the release of the"/>
 <result pre="observed in patients infected with SARS or MERS (with a" exact="prevalence" post="of 10% and 30%, respectively)12â€&quot;14,43,44. A series of reports"/>
 <result pre="who were hospitalized with COVID-19 by 2 January 2020, the" exact="prevalence" post="of any comorbidity was 32% and the most common"/>
 <result pre="diabetes (20%), hypertension (15%) and other CVDs (15%)17. The high" exact="prevalence" post="of these comorbidities was confirmed in subsequent studies18â€&quot;22,45â€&quot;47. Importantly,"/>
 <result pre="of these comorbidities was confirmed in subsequent studies18â€&quot;22,45â€&quot;47. Importantly, the" exact="prevalence" post="of these pre-existing conditions was higher in critically ill"/>
 <result pre="care unit; NR, not reported. A similar trend in the" exact="prevalence" post="of comorbidities has been reported by researchers in other"/>
 <result pre="Of note, this study from New York highlighted the high" exact="prevalence" post="of comorbid obesity among patients with COVID-19, which had"/>
 <result pre="patients in China probably owing to differences in the background" exact="prevalence" post="of obesity between the USA and China. Investigators in"/>
 <result pre="to systemic causes rather than a result of direct viral" exact="infection" post="of the heart53. By contrast, several case reports have"/>
 <result pre="plaque ruptures67. Direct endothelial or vascular injury caused by SARS-CoV-2" exact="infection" post="might also increase the risk of thrombus formation and"/>
 <result pre="stages of COVID-19, the response of the immune system to" exact="infection" post="might trigger the development of stress-induced cardiomyopathy or cytokine-related"/>
 <result pre="findings are suggestive of a new phenomenon caused by SARS-CoV-2" exact="infection" post="in children that can lead to a hyperinflammatory syndrome"/>
 <result pre="need to screen for COVID-19. Given that individuals with SARS-CoV-2" exact="infection" post="might be asymptomatic, routine screening of donor tissues is"/>
 <result pre="Given that individuals with SARS-CoV-2 infection might be asymptomatic, routine" exact="screening" post="of donor tissues is necessary during the pandemic. Screening"/>
 <result pre="transplantation will also be required to avoid worsening of subclinical" exact="infection" post="after starting immunosuppression. As with patients with CVD, patients"/>
 <result pre="risk factors (such as hypertension and diabetes), cardiotoxicity of cancer" exact="treatment" post="and/or cardiovascular damage by COVID-19, combined with their impaired"/>
 <result pre="during the pandemic is to balance the risk of SARS-CoV-2" exact="infection" post="with the need to provide timely cancer treatment. Clinicians"/>
 <result pre="cancer treatment. Clinicians need to determine the optimal timing of" exact="treatment" post="in patients with cancer and cardiovascular comorbidities, especially if"/>
 <result pre="they are infected with or exposed to SARS-CoV-2. Routine COVID-19" exact="screening" post="might be necessary before cancer treatment to avoid worsening"/>
 <result pre="to SARS-CoV-2. Routine COVID-19 screening might be necessary before cancer" exact="treatment" post="to avoid worsening of a subclinical infection. ACE2 and"/>
 <result pre="the biological mechanism underlying tissue-specific infection. As with SARS-CoV, SARS-CoV-2" exact="infection" post="is triggered by binding of viral SÂ protein to"/>
 <result pre="host cell infection. ToÂ date, clinical evidence of direct viral" exact="infection" post="of cardiomyocytes has not been found. Given that myocarditis"/>
 <result pre="has not been found. Given that myocarditis related to SARS-CoV-2" exact="infection" post="is rare23,53, the interaction between SARS-CoV-2 and ACE2 might"/>
 <result pre="model of ARDS, Ace2 knockout exacerbated acute lung injury, whereas" exact="treatment" post="with recombinant ACE2 rescued lung damage106. Therefore, like SARS-CoV,"/>
 <result pre="with recombinant ACE2 rescued lung damage106. Therefore, like SARS-CoV, SARS-CoV-2" exact="infection" post="might result in the downregulation of ACE2, which can"/>
 <result pre="RAAS, is upregulated in many diseases and is a common" exact="treatment" post="target for various cardiovascular disorders61,100,113. ACE2 inactivates angiotensin II"/>
 <result pre="exogenous administration of recombinant human ACE2 (rhACE2) can prevent SARS-CoV-2" exact="infection" post="by acting as a decoy114. The investigators demonstrated that"/>
 <result pre="decoy114. The investigators demonstrated that clinical-grade rhACE2 can reduce SARS-CoV-2" exact="infection" post="in cell culture and in engineered human blood vessel"/>
 <result pre="numerous studies have also reported histological evidence of direct viral" exact="infection" post="in non-respiratory organs such as the heart, brain, liver"/>
 <result pre="or cytokine storm, but might also be caused by direct" exact="infection" post="of numerous organ systems by SARS-CoV-2. Mechanistically, the broad"/>
 <result pre="level of ACE2 expression, inflammation in the endothelium caused by" exact="infection" post="with SARS-CoV-2 might underlie the diverse clinical manifestations of"/>
 <result pre="ACE inhibitors and ARBs are commonly used worldwide for the" exact="treatment" post="of hypertension and other CVDs, whether these drugs should"/>
 <result pre="affects ACE2 directly. Although some animal studies have shown that" exact="treatment" post="with ACE inhibitors or ARBs can increase the expression"/>
 <result pre="conditions such as baseline expression levels of ACE2, dosing and" exact="treatment" post="periods. Second, whether potential upregulation of ACE2 is harmful"/>
 <result pre="of ACE2 by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)" exact="infection" post="might be involved in mediating cardiovascular damage. ARB, angiotensin"/>
 <result pre="focused on the development of drugs for the prevention and" exact="treatment" post="of COVID-19 (ref.41). Of note, the development and testing"/>
 <result pre="and treatment of COVID-19 (ref.41). Of note, the development and" exact="testing" post="of new drugs are time-consuming processes139 and not a"/>
 <result pre="azithromycin Chloroquine and hydroxychloroquine have been widely touted as potential" exact="treatment" post="strategies for COVID-19 (refs143â€&quot;145). Chloroquine and hydroxychloroquine can potentially"/>
 <result pre="autophagy and lysosomal activity41. Both drugs are used in the" exact="treatment" post="of malaria and chronic inflammatory diseases such as systemic"/>
 <result pre="involving 62 patients with COVID-19 in China, patients in the" exact="treatment" post="group received hydroxychloroquine (400â€‰mg per day) for 5 days,"/>
 <result pre="5 days, whereas patients in the control group received standard" exact="treatment" post="(oxygen therapy, antiviral agents, antibacterial agents and immunoglobulin, with"/>
 <result pre="time, cough remission time and pneumonia-related symptoms compared with standard" exact="treatment" post="alone. Furthermore, in a retrospective study from Wuhan involving"/>
 <result pre="was significantly lower among patients treated with hydroxychloroquine plus standard" exact="treatment" post="(which included other antiviral drugs and antibiotics) compared with"/>
 <result pre="(which included other antiviral drugs and antibiotics) compared with standard" exact="treatment" post="alone (18.8% versus 47.4%)148. However, in a large observational"/>
 <result pre="observational study involving 1,376Â patients from New York City, hydroxychloroquine" exact="treatment" post="did not alter the risk of the composite end"/>
 <result pre="which has been assessed in combination with hydroxychloroquine as a" exact="treatment" post="for COVID-19, is also known to prolong the QT"/>
 <result pre="study of 1,438 patients hospitalized with COVID-19 in New York," exact="treatment" post="with hydroxychloroquine, azithromycin or both was compared with neither"/>
 <result pre="Remdesivir Remdesivir is a promising investigational nucleotide analogue for the" exact="treatment" post="of COVID-19 that has broad-spectrum antiviral activity and functions"/>
 <result pre="functions by targeting RdRP27,154,155. Remdesivir was originally developed for the" exact="treatment" post="of Ebola virus disease. Prophylactic and therapeutic administration of"/>
 <result pre="COVID-19 in May 2020 to meet the urgent demand for" exact="treatment" post="of hospitalized patients158. The optimal dosing and duration of"/>
 <result pre="treatment of hospitalized patients158. The optimal dosing and duration of" exact="treatment" post="is still under investigation. Under the emergency use authorization,"/>
 <result pre="still under investigation. Under the emergency use authorization, a 10-day" exact="treatment" post="regimen (200â€‰mg on day 1 followed by 100â€‰mg per"/>
 <result pre="invasive mechanical ventilation and/or extracorporeal membrane oxygenation, and a 5-day" exact="treatment" post="course is suggested for patients with milder symptoms. Although"/>
 <result pre="is a fixed-dose drug combination used for the prevention and" exact="treatment" post="of HIV infection and works by inhibiting protease activity159."/>
 <result pre="drug combination used for the prevention and treatment of HIV" exact="infection" post="and works by inhibiting protease activity159. Lopinavir is available"/>
 <result pre="199 patients with COVID-19, no benefit was observed with lopinavirâ€&quot;ritonavir" exact="treatment" post="compared with standard care159. Gastrointestinal adverse effects were more"/>
 <result pre="Gastrointestinal adverse effects were more frequently reported in the lopinavirâ€&quot;ritonavir" exact="treatment" post="group than in the standard group, but adverse cardiovascular"/>
 <result pre="this interaction is a potential target for the prevention and" exact="treatment" post="of COVID-19. Several hurdles need to be overcome in"/>
 <result pre="ACE2, other animal species that are naturally susceptible to SARS-CoV-2" exact="infection" post="(such as ferrets, hamsters and non-human primates)164,165,167â€&quot;170 or in"/>
 <result pre="for COVID-19, our main strategy to combat the pandemic is" exact="social distancing." post="The capacity of health-care systems globally has been severely"/>
 <result pre="take 12â€&quot;18Â months34. To meet the urgent need for effective" exact="treatment" post="and preventative strategies, a concerted effort must be made"/>
 <result pre="can be triggered by a variety of factors such as" exact="infection" post="and drugs. Tissue tropism The ability of a given"/>
 <result pre="54.WangDet al.Chinese Society of Cardiology expert consensus statement on the" exact="diagnosis" post="and treatment of adult fulminant myocarditisSci. China Life Sci.20196218720230519877"/>
 <result pre="Society of Cardiology expert consensus statement on the diagnosis and" exact="treatment" post="of adult fulminant myocarditisSci. China Life Sci.20196218720230519877 55.InciardiRMet al.Cardiac"/>
 <result pre="68.BentzonJFOtsukaFVirmaniRFalkEMechanisms of plaque formation and ruptureCirc. Res.20141141852186624902970 69.VargaZet al.Endothelial cell" exact="infection" post="and endotheliitis in COVID-19Lancet20203951417141832325026 70.GarciaSet al.Reduction in ST-segment elevation"/>
 <result pre="in patients with COVID-19 pneumoniaJ. Vasc. Surg.202010.1016/j.jvs.2020.04.48332360679 89.ParanjpeIet al.Association of" exact="treatment" post="dose anticoagulation with in-hospital survival among hospitalized patients with"/>
 <result pre="among hospitalized patients with COVID-19J. Am. Coll. Cardiol.20207612212432387623 90.TangNet al.Anticoagulant" exact="treatment" post="is associated with decreased mortality in severe coronavirus disease"/>
 <result pre="of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers with" exact="testing" post="positive for coronavirus disease 2019 (COVID-19)JAMA Cardiol.202010.1001/jamacardio.2020.185532432651 129.IshiyamaYet al.Upregulation"/>
 <result pre="(2020). 144.Gautret, P. et al. Hydroxychloroquine and azithromycin as a" exact="treatment" post="of COVID-19: results of an open-label non-randomized clinical trial."/>
 <result pre="of hydroxychloroquine with or without concomitant azithromycin among hospitalized patients" exact="testing" post="positive for coronavirus disease 2019 (COVID-19)JAMA Cardiol.202010.1001/jamacardio.2020.183432356863 152.HancoxJCHasnainMViewegWVCrouseELBaranchukAAzithromycin, cardiovascular"/>
 <result pre="study of case reportsTher. Adv. Infect. Dis.2013115516525165550 153.RosenbergESet al.Association of" exact="treatment" post="with hydroxychloroquine or azithromycin with in-hospital mortality in patients"/>
 <result pre="and interferon beta against MERS-CoVNat. Commun.20201122231924756 157.BeigelJHet al.Remdesivir for the" exact="treatment" post="of COVID-19 â€&quot; preliminary reportN. Engl. J. Med.202010.1056/NEJMoa200776432663912 158.US"/>
 <result pre="with severe COVID-19N. Engl. J. Med.20203821787179932187464 160.StockmanLJBellamyRGarnerPSARS: systematic review of" exact="treatment" post="effectsPLoS Med.20063e34316968120 161.Centers for Disease Control and Prevention. Interim"/>
 <result pre="dogs, and other domesticated animals to SARS-coronavirus 2Science20203681016102032269068 166.McCrayPBJr.et al.Lethal" exact="infection" post="of K18-hACE2 mice infected with severe acute respiratory syndrome"/>
 <result pre="of severe fever with thrombocytopenia syndrome phlebovirus for human lethal" exact="infection" post="and pathogenesisNat. Microbiol.2019443844630531978 169.ChanJFet al.Simulation of the clinical and"/>
</results>
